



**Kalydeco (Ivacaftor)**  
**Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit  
 Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

**URGENT**

MEMBER INFORMATION	
LAST NAME:	FIRST NAME:
PHONE NUMBER:	DATE OF BIRTH:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
PATIENT INSURANCE ID NUMBER:	

MALE  FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI DISCLOSURE AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_  
 AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

*Continued on next page*





**Kalydeco (Ivacaftor)**  
**Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit  
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

<b>1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?</b> <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
<b>MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):</b>  	<b>DURATION OF THERAPY (SPECIFY DATES):</b>  	<b>RESPONSE/REASON FOR FAILURE/ALLERGY:</b>  
<b>2. LIST DIAGNOSES:</b>  		<b>ICD-10:</b>  
<b>3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.</b>		
<p><b>Clinical Information:</b></p> <p>Is this request for initial therapy (meaning the patient has not received therapy with Kalydeco in the past AND there are no paid claims for Kalydeco in member's history)? <input type="checkbox"/> Yes <input type="checkbox"/> No  <i>If No, please complete "Renewal Therapy" section below.</i></p> <p><b>Initial Request:</b></p> <p>Does the patient have a diagnosis of cystic fibrosis? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have a CFTR gene mutation listed within the current FDA prescribing information?  <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Test documentation must be provided</i></p> <p>Is documentation available showing this patient's most recent (baseline) FVC measurement, obtained within the past 30 days, to be greater than or equal to 40% predicted? <input type="checkbox"/> Yes <input type="checkbox"/> No  <i>Please submit this documentation, e.g., chart notes.</i></p> <p>Is documentation available showing this patient's most recent (baseline) measurements for FEV1 and FEV1 percentage of predicted, obtained within the past 30 days while the patient is NOT receiving treatment with Kalydeco? <input type="checkbox"/> Yes <input type="checkbox"/> No  <i>Please submit this documentation, e.g., chart notes</i></p> <p><u>If requesting Kalydeco Granules also answering the following:</u></p> <p><b>Renewal Therapy</b>        You must answer ALL of the following questions:</p> <p>Is this request for initial therapy (meaning the patient has not received therapy with Kalydeco in the past AND there are no paid claims for Kalydeco in member's history)? <input type="checkbox"/> Yes <input type="checkbox"/> No  <i>If Yes, please complete "Initial Therapy" section above.</i></p>		





**Kalydeco (Ivacaftor)  
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Is this request for renewal of therapy (meaning the patient is currently receiving therapy AND paid claims are in member's history)?  Yes  No

*Note: use of samples only and/or access through patient assistance program only does not qualify as current therapy subject to renewal; those should be submitted as initial therapy instead.*

***If No, please complete "Initial Therapy" section above.***

Is documentation available which shows the patient's current FEV1 measurements?  Yes  No

*Current FEV1 measurements are defined as the most recent FEV1 and FEV1 percentage of predicted that were measured within the previous 30 days while the patient is receiving treatment with Kalydeco.*

*Please submit this documentation, such as chart notes.*

Does the patient have the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene?  Yes  No

Does the patient have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene?  Yes  No

Is the patient's current FEV1 percentage of predicted increased by at least 5 absolute percentage points greater than the baseline FEV1 percentage of predicted?  Yes  No

*Baseline FEV1 percentage of predicted is defined as the most recent FEV1 percentage of predicted that was measured while the patient was not receiving treatment with Kalydeco.*

*Please submit this documentation, such as chart notes*

Is the patient's current FEV1 percentage of predicted increased by at least 8.60 absolute percentage points greater than the baseline FEV1 percentage of predicted?  Yes  No

*Baseline FEV1 percentage of predicted is defined as the most recent FEV1 percentage of predicted that was measured while the patient was not receiving treatment with Kalydeco.*

*Please submit this documentation, such as chart notes*

Is the patient's current FEV1 percentage of predicted increased by at least 10 absolute percentage points greater than the baseline FEV1 percentage of predicted?  Yes  No

*Baseline FEV1 percentage of predicted is defined as the most recent FEV1 percentage of predicted that was measured while the patient was not receiving treatment with Kalydeco.*

*Please submit this documentation, such as chart notes*





**Kalydeco (Ivacaftor)  
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

**MEMBER'S LAST NAME:** \_\_\_\_\_ **MEMBER'S FIRST NAME:** \_\_\_\_\_

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

\_\_\_\_\_

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature or Electronic I.D. Verification:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO: 800-424-7640**

**MAIL REQUESTS TO:** Magellan Rx Management Prior Authorization Program; c/o Magellan Health, Inc.  
4801 E. Washington Street, Phoenix, AZ 85034  
Phone: 877-228-7909

